Publicaciones en las que colabora con A. Redondo Sánchez (29)

2023

  1. Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus

    Journal of gynecologic oncology, Vol. 34, Núm. 5, pp. e57

  2. Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3519-3526

2022

  1. Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models

    Frontiers in Oncology, Vol. 12

  2. Dostarlimab for the treatment of advanced endometrial cancer

    Expert Review of Clinical Pharmacology, Vol. 15, Núm. 1, pp. 1-9

  3. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?

    Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 536-542

  2. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma

    Virchows Archiv, Vol. 479, Núm. 6, pp. 1167-1176

  3. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    The Lancet. Oncology, Vol. 22, Núm. 5, pp. 609-619

  4. Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience

    Clinical and Translational Oncology, Vol. 23, Núm. 6, pp. 1245-1252

  5. Management of advanced ovarian cancer in Spain: an expert Delphi consensus

    Journal of Ovarian Research, Vol. 14, Núm. 1

  6. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

    ESMO open, Vol. 6, Núm. 4, pp. 100212

  7. SEOM clinical guideline in ovarian cancer (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 961-968

2020

  1. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

  2. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer

    Gynecologic Oncology, Vol. 159, Núm. 1, pp. 142-149

  3. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas

    Clinical and Translational Oncology, Vol. 22, Núm. 10, pp. 1849-1856

2019

  1. Myoinvasive pattern as a prognostic marker in low-grade, early-stage endometrioid endometrial carcinoma

    Cancers, Vol. 11, Núm. 12

  2. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402

  3. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

    International Journal of Gynecological Cancer, Vol. 29, Núm. 7, pp. 1141-1147

  4. Tratamiento sistémico de primera línea: Quimioterapia intraperitoneal

    Ginecología oncológica: manual práctico (Editorial Médica Panamericana), pp. 265-272

2018

  1. Correction to: SEOM clinical guidelines for endometrial cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (29-37), 10.1007/s12094-017-1809-9)

    Clinical and Translational Oncology